@aleksanderkrag.bsky.social
To Screen—or not to screen for for advanced steatotic liver disease that’s the question? Our new @lancetgastrohep.bsky.social review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria @Stine Johansen authors.elsevier.com/c/1lRV98nByr...
New Review - Screening for advanced steatotic liver disease www.thelancet.com/journals/lan... #LiverSky #MedSky @aleksanderkrag.bsky.social
Screening for advanced steatotic liver disease
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...
thelancet.com
APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol" www.nature.com/articles/s41... #Liversky
Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more! www.nature.com/nrgastro/vol...
🧪 New findings published in @jhepatology.bsky.social JHEP reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect histological disease activity in MASLD/MASH patients in response to treatment. doi.org/10.1016/j.jh...
Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency? Proud of being part of this project - Deep Visual Proteomics at single cell level 👉in @nature.com www.nature.com/articles/s41...
Check out the “Steatotic Liver Disease Burden Paradox “ pubmed.ncbi.nlm.nih.gov/39639157/
Nature Reviews Gastroenterology & Hepatology@natrevgastrohep.nature.com · 2y agoOur APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more! www.nature.com/nrgastro/vol...
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️ Over 60% with MetALD/ALD and 38% with MASLD change subclass. This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐 Link: www.cghjournal.org/article/S154...
Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments
Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...
cghjournal.org
In today’s #readoftheweek📚 learn why accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with #steatoticliverdisease & when designing clinical trials. Read now: www.jhep-reports.eu/article/S258... 🙏 @aleksanderkrag.bsky.social @majathiele.bsky.social et al.
#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.! easl.eu/easl-studio-...
AlbTrial Update 🏥 70 out of 240 included But what is AlbTrial? AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis. 🔗 bmjopen.bmj.com/content/bmjo... 🧵below Annual General Assembly in MicrobPredict #liversky #cirrhosis
What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease? @aleksanderkrag.bsky.social and colleagues discuss… www.thelancet.com/journals/lan... #GastroSky #MedSky
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD
For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic lipid metabolism, causing steatosis, can result from several factors predomin...
thelancet.com
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD - MASLD VS MetALD/ALD is not 10:1 - more likely 1:1😳 - The Lancet Gastroenterology & Hepatology www.thelancet.com/journals/lan...
Joined a great meeting in Helsinki recently and had the pleasure of seeing but not understanding the new nomenclature of Steatotic liver disease in Finnish😀
2025 is the perfect year to take your career to the next level🚀 There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force. Apply by 20 January: easl.eu/leadership25 #LiverSky
Two days of finalizing the narrative and recommendations of the second EASL @thelancet.bsky.social Commission in Geneva. Now we write the report! @aleksanderkrag.bsky.social
EASL Governing Board meeting - working for the community❤️ 👉SLD and LCS summits 👉EASL schools / what and where? 👉EiC @JHepatology @JHEP_Reports new initiatives🤩 👉 X vs @bluesky ? 👉AI Task Force 👉#EASLCongress 2025 Amsterdam 👉Register grants 👉Global collaboration
@EASL @AASLD MASTERCLASS in beautiful Savannah ❤️ Gathering of next generation of leaders in hepatology🤩🤩 👉team science 👉building a team Networking
Ever heard about the “Steatotic Liver Disease burden paradox”? Check it out 👇👇👇 Perspective in @natureportfolio.bsky.social rdcu.be/d2wcV
Remember deadline for abstract EASLCongress 2025 in Amsterdam December 3rd !!
After a successful #TLM24 AASLD in San Diego - thanks Ray Kim and Paul Kwo for a fantastic hospitality at @stanfordpress.bsky.social
